INCY:NGS-Incyte Corporation

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 85.34

Change

0.00 (0.00)%

Market Cap

USD 20.12B

Volume

1.53M

Analyst Target

USD 89.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.14 (-0.27%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

+2.75 (+0.29%)

USD 106.98B
MRNA Moderna Inc

+3.18 (+2.96%)

USD 39.68B
ARGX argenx NV ADR

+1.02 (+0.26%)

USD 23.67B
BNTX BioNTech SE

+1.27 (+1.38%)

USD 22.34B
GMAB Genmab AS

-0.20 (-0.65%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

+2.42 (+1.59%)

USD 19.08B
RPRX Royalty Pharma Plc

+0.22 (+0.73%)

USD 18.18B
BGNE BeiGene Ltd

+1.27 (+0.83%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

+0.87 (+0.99%)

USD 16.06B

ETFs Containing INCY

XDNA:CA iShares Genomics Immunolo.. 3.78 % 0.00 %

N/A

CAD 5.07M
BIS ProShares UltraShort Nasd.. 2.09 % 0.95 %

-0.50 (0.00%)

USD 3.90M
MRND 1.89 % 0.00 %

N/A

N/A
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

+0.37 (+0.00%)

USD 0.14B
UBIO 0.00 % 0.95 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.20% 64% D 84% B
Dividend Return N/A N/A N/A N/A F
Total Return 34.20% 64% D 83% B
Trailing 12 Months  
Capital Gain 2.75% 72% C 66% D+
Dividend Return N/A N/A N/A N/A F
Total Return 2.75% 71% C- 61% D-
Trailing 5 Years  
Capital Gain 53.21% 79% B- 71% C-
Dividend Return N/A N/A N/A N/A F
Total Return 53.21% 78% C+ 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 17.34% 67% D+ 74% C
Dividend Return 17.34% 66% D+ 72% C
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 57.28% 39% F 15% F
Risk Adjusted Return 30.26% 67% D+ 47% F
Market Capitalization 20.12B 99% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 136.80 1% 2%
Price/Book Ratio 10.10 12% 10%
Price / Cash Flow Ratio 15.69 2% 4%
Price/Free Cash Flow Ratio 69.38 3% 6%
Management Effectiveness  
Return on Equity 6.18% 86% 54%
Return on Invested Capital 8.68% 89% 67%
Return on Assets 4.44% 94% 76%
Debt to Equity Ratio 1.25% 69% 89%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.